Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19

Set Alert for Coronavirus COVID-19

CanSino's Inhaled COVID Vaccine Shows Early Promise As Potential Booster

Early study results show CanSino’s inhaled vaccine for COVID-19 triggered an immune response similar to its injected counterpart.

Pandemic Still Weighs On Gilead’s HIV Business, But Signs Of Recovery

HIV PrEP and treatments saw increases in sales, though the US treatment market’s recovery was slower than expected and may need “several” quarters to return to pre-pandemic levels.

GSK Exceeds Expectations In Q2, But Still Awaiting Shingrix Bounce Back

While demand for Shingrix is expected to return in the US, the slow process of COVID-19 vaccination in many other countries will delay its uptake.

Dr Reddy’s Gears For Sputnik Light In India, Jab For Adolescents

Dr Reddy’s is to press ahead with India filing plans for single-dose COVID-19 vaccine Sputnik Light and also expects to “build on” the Russian partner’s trial in adolescents of the two-dose Sputnik V. The company also pilots a partnered first-of-its-kind cashless digital health offering.

Pfizer On Boosters, Kids And Prospects For A Long-Term COVID-19 Business

The company raised revenue guidance for its COVID-19 vaccine this year to a staggering $33bn from a prior estimate of $26bn.

Takeda To Build On COVID-19 Awareness For Its Dengue Vaccine

Takeda’s vaccines chief Rajeev Venkayya tells Scrip about its COVID-19 vaccines partnerships, and how the pandemic can stimulate action against other infectious disease threats such as Dengue.

Stock Watch: Investors Reward Those Who Raise Their Guidance

Oncology diagnoses and therefore revenues are returning as we emerge from the pandemic, but the recovery also brings the challenges of reduced diagnostic and eventually vaccine revenues.

Low Sinopharm Protection In Elderly Casts New Doubt On Chinese COVID-19 Vaccines

A new study in over 400 people reignites fears about the apparent low efficacy of Chinese COVID-19 vaccines, especially among the elderly, and adding to the debate around the need for booster shots.

Will Health Insurance In India Pinch Your Pocket Post COVID-19?

While a Star Health study found high hospitalization costs for COVID-19 patients in India, those vaccinated paid 24% less and faced 81% lower mortality risk. However, insurers are unlikely to offer lower premiums to those vaccinated, even as the prospects for an overall hike remain uncertain, say experts.

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: J&J’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19.

Where To Start Tackling ‘Long Covid’? PureTech Pioneers Lung Drug Trial

PureTech is among the very first companies to attempt to treat long Covid and hopes its anti-fibrosis drug can aid patients’ recovery

J&J's COVID-19 Vaccine On Track To Generate $2.5bn This Year

The company's pharma revenues grew 17.2% in the second quarter against favorable comparisons and as the COVID-19 pandemic recovery continued.

Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing

Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.

ImmunityBio Sees Booster Role For Under-The-Tongue COVID-19 Vaccine

In search of a differentiated approach, ImmunityBio’s candidate aims to boostT-cell immune responses via a subcutaneous and oral vaccine combination.

Global Herd Immunity Against COVID-19 Unlikely, Says Ebola Vaccine Developer

As coronavirus variants keep emerging, global herd immunity is unlikely, says Steven Jones, one of the developers of the first Ebola vaccine. In a wide-ranging discussion with McKinsey, he and other experts weighed in on ways to live with COVID-19, which is expected to soon become endemic.

Coronavirus Update: Japan Approves Antibody Cocktail In Short Order

Japan has granted an emergency approval to Chugai/Roche/Regeneron's antibody cocktail after a rapid review, while India has emerged as one of the top purchasers globally of COVID-19 vaccines as it looks to protect more of its population. 

See All
UsernamePublicRestriction

Register